Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2015 (2015), Article ID 592170, 4 pages
http://dx.doi.org/10.1155/2015/592170
Case Report

Dual Effect of Ziconotide in Primary Erythromelalgia

1Pain Therapy Unit, Department of Hematology and Oncology, Pugliese-Ciaccio Hospital, Catanzaro, Italy
2Department of Pharmacy and Health and Nutritional Sciences, University of Calabria, Italy
3Molecular Biology Unit, Department of Hematology and Oncology, Pugliese-Ciaccio Hospital, Catanzaro, Italy

Received 15 July 2015; Revised 20 October 2015; Accepted 21 October 2015

Academic Editor: Piotr K. Janicki

Copyright © 2015 Rosario Russo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. D. P. Davis, W. M. O'Fallon, R. S. Rogers III, and T. W. Rooke, “Natural history of erythromelalgia: presentation and outcome in 168 patients,” Archives of Dermatology, vol. 136, no. 3, pp. 330–336, 2000. View at Google Scholar · View at Scopus
  2. K. Kvernebo, “Erythromelalgia: a condition caused by microvascular arteriovenous shunting,” Vasa—European Journal of Vascular Medicine, vol. 51, pp. 1–39, 1998. View at Google Scholar
  3. V. Latessa, “Erythromelalgia: a rare microvascular disease,” Journal of Vascular Nursing, vol. 28, no. 2, pp. 67–71, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. M. P. Davis and T. W. Rooke, “Erythromelalgia,” in Vascular Medicine: A Companion to Braunwald's Heart Disease, M. A. Creager, V. J. Dzau, and J. Loscalzo, Eds., pp. 711–721, Elsevier, Philadelphia, Pa, USA, 2006. View at Google Scholar
  5. M. D. P. Davis and T. Rooke, “Erythromelalgia,” Current Treatment Options in Cardiovascular Medicine, vol. 8, no. 2, pp. 153–165, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. J. D. Stone, M. P. Rivey, and D. R. Allington, “Nitroprusside treatment of erythromelalgia in an adolescent female,” Annals of Pharmacotherapy, vol. 31, no. 5, pp. 590–592, 1997. View at Google Scholar · View at Scopus
  7. L. Zhang, W.-H. Wang, L.-F. Li et al., “Long-term remission of primary erythermalgia with R1150W polymorphism in SCN9A after chemical lumbar sympathectomy,” European Journal of Dermatology, vol. 20, no. 6, pp. 763–767, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. M. A. Thimineur, E. Kravitz, and M. S. Vodapally, “Intrathecal opioid treatment for chronic non-malignant pain: a 3-year prospective study,” Pain, vol. 109, no. 3, pp. 242–249, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. V. C. Anderson and K. J. Burchiel, “A prospective study of long-term intrathecal morphine in the management of chronic nonmalignant pain,” Neurosurgery, vol. 44, no. 2, pp. 289–300, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. D. F. J. Zech, S. Grond, J. Lynch, D. Hertel, and K. A. Lehmann, “Validation of World Health Organization guidelines for cancer pain relief: a 10-year prospective study,” Pain, vol. 63, no. 1, pp. 65–76, 1995. View at Publisher · View at Google Scholar · View at Scopus
  11. A. M. Gilson, K. M. Ryan, D. E. Joranson, and J. L. Dahl, “A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997–2002,” Journal of Pain and Symptom Management, vol. 28, no. 2, pp. 176–188, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. T. A. Bowdle, “Adverse effects of opioid agonists and agonist-antagonists in anaesthesia,” Drug Safety, vol. 19, no. 3, pp. 173–189, 1998. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Mercadante, “Problems of long-term spinal opioid treatment in advanced cancer patients,” Pain, vol. 79, no. 1, pp. 1–13, 1999. View at Publisher · View at Google Scholar · View at Scopus
  14. B. M. Olivera, J. Rivier, C. Clark et al., “Diversity of Conus neuropeptides,” Science, vol. 249, no. 4966, pp. 257–263, 1990. View at Publisher · View at Google Scholar · View at Scopus
  15. B. M. Olivera, L. J. Cruz, V. de Santos et al., “Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using omega-conotoxin from Conus magus venom,” Biochemistry, vol. 26, no. 8, pp. 2086–2090, 1987. View at Publisher · View at Google Scholar · View at Scopus
  16. G. P. Miljanich and J. Ramachandran, “Antagonists of neuronal calcium channels: structure, function, and therapeutic implications,” Annual Review of Pharmacology and Toxicology, vol. 35, pp. 707–734, 1995. View at Publisher · View at Google Scholar · View at Scopus
  17. Y.-X. Wang and S. S. Bowersox, “Analgesic properties of ziconotide, a selective blocker of N-type neuronal calcium channels,” CNS Drug Reviews, vol. 6, no. 1, pp. 1–20, 2000. View at Google Scholar · View at Scopus
  18. W. G. Brose, D. P. Gutlove, R. R. Luther, S. S. Bowersox, and D. McGuire, “Use of intrathecal SNX-111, a novel, N-type, voltage-sensitive, calcium channel blocker, in the management of intractable brachial plexus avulsion pain,” The Clinical Journal of Pain, vol. 13, no. 3, pp. 256–259, 1997. View at Publisher · View at Google Scholar · View at Scopus
  19. J. G. McGivern, “Ziconotide: a review of its pharmacology and use in the treatment of pain,” Neuropsychiatric Disease and Treatment, vol. 3, no. 1, pp. 69–85, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. J. A. DeLeo and R. P. Yezierski, “The role of neuroinflammation and neuroimmune activation in persistent pain,” Pain, vol. 90, no. 1-2, pp. 1–6, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Jancsó, A. Jancsó-Gábor, and J. Szolcsányi, “Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin.,” British Journal of Pharmacology, vol. 31, no. 1, pp. 138–151, 1967. View at Google Scholar · View at Scopus
  22. N. Jancsó, A. Jancsó-Gábor, and J. Szolcsányi, “The role of sensory nerve endings in neurogenic inflammation induced in human skin and in the eye and paw of the rat,” British Journal of Pharmacology, vol. 33, no. 1, pp. 32–41, 1968. View at Google Scholar · View at Scopus
  23. W. D. Willis Jr., “Dorsal root potentials and dorsal root reflexes: a double-edged sword,” Experimental Brain Research, vol. 124, no. 4, pp. 395–421, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. J. C. Hunter and J. E. Maggio, “Pharmacological characterisation of a novel tachykinin isolated from mammalian spinal cord,” European Journal of Pharmacology, vol. 97, no. 1-2, pp. 159–160, 1984. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Gamse and A. Saria, “Potentiation of tachykinin-induced plasma protein extravasation by calcitonin gene-related peptide,” European Journal of Pharmacology, vol. 114, no. 1, pp. 61–66, 1985. View at Publisher · View at Google Scholar · View at Scopus